PMID- 24844775
OWN - NLM
STAT- MEDLINE
DCOM- 20141229
LR  - 20220317
IS  - 1534-6285 (Electronic)
IS  - 1527-2737 (Print)
IS  - 1527-2737 (Linking)
VI  - 15
IP  - 7
DP  - 2014 Jul
TI  - Implications of the new AUA guidelines on prostate cancer detection in the U.S.
PG  - 420
LID - 10.1007/s11934-014-0420-7 [doi]
AB  - In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a blanket "D" 
      recommendation against all prostate-specific antigen (PSA)-based early detection 
      efforts for prostate cancer, reflecting critical misinterpretations of the major 
      evidence regarding benefits and harms of such testing. Against the backdrop of 
      the ensuing controversy, in 2013 the American Urological Association (AUA) 
      published a new, methodologically rigorous guideline. This guideline recommended 
      that men aged 55-69 be offered biennial screening in the setting of shared 
      decision-making, that men under 40 or over 69 years of age should not be screened 
      routinely, and that evidence was insufficient to recommend screening for men aged 
      40-54 years. While it has received criticism with regard to the age-based 
      recommendations, the AUA guideline reflects a far better and more balanced 
      presentation of the available evidence than the USPSTF statement. However, 
      because the USPSTF is far more influential than the AUA among primary care 
      providers, the ultimate impact of the new AUA guideline on practice patterns may 
      be limited. Optimizing early detection practices should involve 
      consensus-building incorporating both primary care and specialist input, with the 
      goals of minimizing overtreatment of low-risk disease while continuing to reduce 
      prostate cancer mortality rates through early detection and aggressive management 
      of high-risk disease.
FAU - Cooperberg, Matthew R
AU  - Cooperberg MR
AD  - Departments of Urology and Epidemiology & Biostatistics, University of 
      California, San Francisco, Box 1695, 1600 Divisadero Street, A-624, San 
      Francisco, CA, 94143-1695, USA, mcooperberg@urology.ucsf.edu.
LA  - eng
GR  - R01 CA160816/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Curr Urol Rep
JT  - Current urology reports
JID - 100900943
SB  - IM
MH  - Early Detection of Cancer/*standards
MH  - Humans
MH  - Male
MH  - Practice Guidelines as Topic
MH  - Prostatic Neoplasms/*diagnosis
MH  - Societies, Medical
MH  - United States
MH  - Urology
PMC - PMC6586415
MID - NIHMS597555
COIS- Conflict of Interest Dr. Matthew R. Cooperberg declares no potential conflicts of 
      interest.
EDAT- 2014/05/23 06:00
MHDA- 2014/12/30 06:00
PMCR- 2019/06/20
CRDT- 2014/05/22 06:00
PHST- 2014/05/22 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
PHST- 2019/06/20 00:00 [pmc-release]
AID - 10.1007/s11934-014-0420-7 [doi]
PST - ppublish
SO  - Curr Urol Rep. 2014 Jul;15(7):420. doi: 10.1007/s11934-014-0420-7.